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Abstract
Purpose Assessment of kidney function evolution after 90Y-
DOTATOC peptide receptor radionuclide therapy (PRRT)
with capped activity administration based on a 37-Gy thresh-
old of biological effective dose (BED) to the kidney.
Methods In a prospective phase II study, patients with metas-
tasized neuroendocrine tumours were evaluated for therapy
using 185 MBq 111In-pentetreotide with amino acid
coinfusion. Planar whole-body images were acquired at four
time-points after injection and kidney volumes were measured
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using CT/MRI. BED to the kidneys was estimated using an
extended BED formula and biexponential renal clearance.
Based on published BED dose–toxicity relationships, we
allowed a maximal kidney BED of 37 Gy; if the calculated
BED exceeded 37 Gy, treatment activity was reduced accord-
ingly. Kidney function was assessed at baseline and at
18months, predominantly using 51Cr-EDTA. The rate of renal
function decline was expressed as annual glomerular filtration
rate loss (aGFRL).
Results Only 22 of 50 patients reached the 18-months time-
point, with most missing patients having died due to disease
progression. In the 22 patients who reached 18 months, no
rapid kidney function deterioration was observed over the
18 months, aGFRL >33 % was not seen, and only three
patients showed an increase of one toxicity grade and one
patient an increase of two grades. No significant correlations
between kidney volume (p=0.35), baseline GFR (p=0.18),
risk factors for renal function loss (p=0.74) and aGFRL were
observed. Among the 28 patients who did not reach
18 months, one developed grade 4 kidney toxicity at
15 months after PRRT.
Conclusion Prospective dosimetry using a 37 Gy BED as the
threshold for kidney toxicity is a good guide for 90Y-
DOTATOC PRRT and is associated with a low risk of rapid
renal function deterioration and evolution to severe
nephrotoxicity.
Keywords PRRT . Dosimetry . Renal function .
90Y-DOTATOC
Introduction
Neuroendocrine tumours (NETs) are a heterogeneous group
of tumours originating from neuroendocrine cells in a number
of different organs. Some of these neoplasms keep the ability
to produce a number of specific bioactive amines and hor-
mones [1]. The most frequent sites of origin are the digestive
tract (including the pancreas) and the lungs. Many NETs
overexpress a specific G-protein-coupled transmembrane re-
ceptor on their cell surface, the somatostatin receptor (SSR),
thus enabling the therapeutic use of somatostatin analogues.
Peptide receptor radionuclide therapy (PRRT) with
radiolabelled somatostatin analogues is a promising tool in
the management of patients with inoperable or metastasized
neuroendocrine tumours. Favourable clinical results have al-
ready been obtained with 1,4,7,10-tetraazacyclododecane-
N,N′,N″,N″-tetraacetic-acid (DOTA)-D-Phe1-Tyr3-octreotide
(DOTATOC) labelled with 90Y, a high-energy β-emitter
[2–4], and with (DOTA)-D-Phe1-Tyr3-Thr8-octreotide
(DOTATATE) labelled with 177Lu, a β/γ-emitter [5, 6].
A clear relationship has been demonstrated between reduc-
tion in tumour volume and the absorbed dose in the tumour,
therefore the aim of clinical PRRT is to deliver the maximal
absorbed dose to the tumour while keeping the absorbed dose
to normal tissues within acceptable limits [7]. Deterioration of
renal function is the activity-limiting toxicity in PRRT. The
radiopeptide is reabsorbed in the proximal tubule and retained
in the interstitium, leading to kidney irradiation. The coad-
ministration of positively charged amino acids, such as L-
lysine and/or L-arginine, that competitively inhibit the proxi-
mal tubular reabsorption of the radiopeptide by binding to the
megalin receptor, results in reductions in the renal dose that
range from 9 % to 53 % [8–11]. Despite kidney protection,
renal failure may become clinically evident years after
radionuclide therapy, especially following the use of
90Y-DOTATOC [12], so kidney toxicity remains an issue
for this therapy. In the six reported patients in whom
histopathology was available, radiation-induced thrombot-
ic microangiopathy was consistently identified in kidney
biopsy samples [13–17]. Bodei et al. [10] have identified
a number of risk factors for kidney toxicity after PRRT:
hypertension (systolic or diastolic blood pressure >140/
90 mmHg), diabetes, age (>60 years), renal morphologi-
cal abnormalities (e.g. large cortical cysts), transarterial
chemoembolization and previous chemotherapy with
nephrotoxic agents. Other predictors, introduced by Imhof
et al. [3], were low baseline glomerular filtration rate
(GFR) and high renal tracer uptake in the SSR whole-
body (WB) scan. Kidney size has also been linked to
kidney toxicity, as described by Pauwels et al. [7] who
found an increased risk in patients with smaller kidneys.
In some series, kidney toxicity has resulted in rapid kid-
ney function deterioration, with annual GFR losses
(aGFRL) of 40 % to even 60 % [18].
We used a dosimetry-based patient-specific therapeutic
regimen in a single-centre phase II trial with 90Y-DOTATOC.
The renal biological effective dose (BED) after four cycles of
90Y-DOTATOC at a fixed activity (1.85 GBq/m2 per cycle)
was estimated before the start of therapy using 111In-
pentetreotide. Based on the method of Barone et al. [18], the
maximal projected BED was fixed at 37 Gy after four cycles
of 90Y-DOTATOC. This BED corresponds to the inflexion
point of the sigmoid kidney dose–effect curve relating kidney
dose to renal function loss which, according to the model
Barone et al., results in a loss in kidney function of 5.2 %
annually [18]. If the kidney BED after four cycles was esti-
mated to exceed 37 Gy, either the treatment was cancelled or
the administered activity of the last treatment was reduced in
order to reduce the estimated BED below 37 Gy; a minimum
of three cycles at 100 % activity was required to proceed to
treatment. We hypothesized that severe and rapid kidney
function loss, defined as a aGFRL of more than 33 %, as
was observed in originally by Barone et al. in 4 of 18 patients
(22 %), would be avoided if the 37 Gy threshold was
not exceeded.
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Materials and methods
Study population
The study group consisted of patients with SSR-positive NETs
enrolled in a phase II single-centre trial with 90Y-DOTATOC
in whom kidney function could be assessed 18 months after
initiation of therapy. All patients were Caucasian. This trial
was approved by the Ethics Commission of the University
Hospitals Leuven, and all patients gave written informed
consent.
First andmainly, we investigated the effects of kidney BED
on kidney function in a cohort comprising 22 of the 50
patients included in the study (11 women and 11 men; age
42 – 79 years, mean: 62±11 years), 20 with a tumour of
gastroenteropancreatic (GEP) origin, 1 with a primary neuro-
endocrine tumour in the lung and 1 with a carcinoid of
unknown primary (CUP), all histologically confirmed. Clini-
cal characteristics, previous therapies and risk factors that
might have affected renal function, according to Bodei et al.
[10], are summarized in Table 1. At baseline, the following
procedures were performed: (1) GFR measurement by radio-
tracer clearance with 51Cr-EDTA, (2) 111In-pentetreotide scin-
tigraphy for dosimetry (see below), and (3) 68Ga-DOTATOC
PET/CT for evaluation of the degree of SSR expression. For
accurate determination of kidney volume, the contrast-
enhanced CT data from the 68Ga-DOTATOC PET/CT scan
or MRI scan were used. The volume of the kidney was not
delineated on the 68Ga-DOTATOC PET images.
Next, in the other 28 treated patients (17 women and 11
men; age 31 – 77 years, mean 57±12 years; 20 with GEP-
NETs, 2 with primary lung NETs, 2 with Merckel cell carci-
nomas, 2 with CUP, and 1 with primary breast and 1 primary
kidney NET), a similar work-up of renal effects at 18 months
after PRRT was not performed as 24 patients died before
18 months (23 because of tumour progression and 1 after
prosthesis surgery for an arthritic hip), 2 patients had not yet
reached the 18-month time-point (15 and 14 months at the
time of this report) and in 2 patients PRRT was ended after
one cycle because of aberrant biodistribution of 68Ga-
DOTATOC imaging at week 7 [19] and we assumed that the
given (cumulative dose) was insufficient to cause nephrotox-
icity. However, we still looked at the evolution of estimated
GFR (eGFR) and kidney toxicity up until the last month
before the patient’s death. Two patients were not enrolled in
the study because the calculated kidney BED was so high that
even a minimum of three cycles at 100 % activity exceeded
37 Gy.
Study design
PRRT consisted of four cycles of 90Y-DOTATOC using
1.85 GBq/m2 per cycle every 8 weeks up to an estimated
kidney BED of 37 Gy. Body surface area values determined
using the formula of Du Bois and Du Bois [20], individual
activities per cycle, total administered activity and the follow-
up period are listed in Table 2.
An infusion of 2,000 ml of an amino acid solution with
6.88 g/l lysine and 10.72 g/l arginine (Proteinsteril® Hepa 8 %
(Fresenius)) was given to inhibit tubular reabsorption of the
radiopeptide starting 30 min before administration of the
radiopharmaceutical and continued up to 4 h after
administration.
Radiolabelling of 90Y-DOTATOC
The procedure is discussed in the supplementary data 1.
111In-pentetreotide dosimetry procedure
111In-pentetreotide (T1/2=67.3 h), prepared from a commer-
cially available kit (OctreoScan; Mallinckrodt Medical B.V.,
Petten, The Netherlands), was used as a surrogate to assess the
kinetic behaviour and biodistribution of 90Y-DOTATOC [21].
The same amino acid solution as that used during PRRT was
infused over 4 h starting 30 min before injection of 185 MBq
111In-pentetreotide to create the same renal uptake conditions
as during 90Y-DOTATOC administration.
In each patient, multiple anterior and posterior WB images
were acquired using a dual head gamma camera (ECAM;
Siemens, Erlangen, Germany) with the following settings:
256×1,024 matrix, medium-energy low-penetration (MELP)
collimators, and 15 % energy window centred at 171 keV
(90 % abundance) and 245 keV (94 % abundance). Imaging
was performed at four time-points after injection using a
standard source with known activity positioned at the feet
for conversion of image counts to activity concentrations in
the organs. The first WB scan was acquired 15 min after
administration of 111In-pentetreotide at 10 cm/min and before
bladder voiding. Subsequent WB scans (after voiding) were
acquired at 4, 24 and 48 h at 5 cm/min. The total body counts
of the first WB scan with full bladder were defined as 100 %
of the administered activity. Counts on the following scans
were expressed as fractions of the injected activity (FIA,
expressed as percentages). Samples of 111In (standard sources
with known activity) were used to perform cross-calibration of
the dose calibrator with (a) a gamma camera (about
1.85MBq) and (b) a well counter (about 0.0185MBq). Scatter
correction was not performed in order to avoid underestima-
tion of the kidney BED and attenuation correction was also
not performed as we were looking at relative and not absolute
values (we used the evolution of activity in one area of the
body as a function of time; when assuming constant attenua-
tion this value is not affected by attenuation). On each WB
scan, regions of interest (ROI) were drawn around the stan-
dard source, total body, spleen, liver and kidneys
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(Supplementary Fig. 1). Geometric mean counts of anterior
and posterior WB scans were calculated within each organ
ROI, background correction was performed and the time-
dependent FIAvalues for the total body, spleen, liver, kidneys
and remainder were calculated. These FIA values were then
converted to the FIA 90Y-DOTATOC activities at the mea-
sured time points, with the simplified assumption that 111In-
pen te t reo t ide and 90Y-DOTATOC have s imi l a r
biodistributions and kinetic profiles [22, 23]. For every region,
nonlinear regression analysis was used to determine the
radiopeptide clearance based on a biexponential model and
the results were used to estimate ã, the time-integrated
activity coefficient, previously known as residence time
(Supplementary Fig 2). The ã values were then used in
the internal dosimetry software program OLINDA/EXM ver-
sion 1.0 (Vanderbilt University, Nashville, TN) for a phantom
model-based computation of the organ absorbed doses [24].
Tomographic views (SPECT) of the abdomen (liver and
kidneys) were acquired at 8 and 24 h after injection using the
same gamma camera as for the WB images with 128×128
matrix, 20 s per view and 72 views over 360°. The SPECT
images were used to visually confirm suspected overestima-
tion of kidney activity on the WB images caused by superim-
position of organs with relatively high tracer uptake
(metastatic foci in the liver or physiological uptake in
an enlarged liver) or excretion (colon). If overestimation
of kidney activity on the planar images was confirmed,
this was recorded. No SPECT-based dosimetry was per-
formed in any of the 22 study patients. In one treated
patient (patient 8) a second dosimetry was performed
because of an acute decrease in kidney function based
on systematic intake of NSAIDS during the first dosim-
etry [25].
Kidney volumes were measured on pretherapeutic trans-
verse CT images (slice thickness 3 mm; 10 of 22 patients) or
MRI images (10 patients, THRIVE images, slice thickness
1.5 mm; 2 patients, T1 images, slice thickness 4 mm)
by drawing ROIs on consecutive transverse slices
Table 1 Clinical characteristics
Patient Sex Age
(years)
Primary tumour Previous therapies Risk factors for renal function loss
1 F 56 Small intestine Surgery, somatostatin analogues Cortical cyst
2 M 59 Small intestine Interferon, somatostatin analogues –
3 M 63 Colon Surgery, chemotherapy, targeted agents (everolimus),
somatostatin analogues, interferon
Age >60 years, diabetes mellitus, nephrotoxic
chemotherapy, a functional left kidney
4 F 56 Small intestine Surgery, somatostatin analogues –
5 M 64 Small intestine Somatostatin analogues Age >60 years, diabetes mellitus, hypertension,
cortical cysts
6 M 69 Small intestine Surgery, somatostatin analogues Age >60 years, hypertension, cortical cysts
7 F 78 Carcinoid of
unknown
primary
Radiation, somatostatin analogues Age >60 years, diabetes mellitus, hypertension
8 M 69 Small intestine Surgery, somatostatin analogues Age >60 years
9 F 80 Small intestine Everolimus, somatostatin analogues Age >60 years, hypertension, cortical cysts
10 F 55 Small intestine Surgery, interferon, somatostatin analogues,
transarterial chemoembolization
Transarterial chemoembolization
11 M 50 Rectum Surgery, somatostatin analogues –
12 M 75 Pancreas Sutent, somatostatin analogues Age >60 years, hypertension
13 M 55 Small intestine Surgery, somatostatin analogues Hypertension
14 F 68 Small intestine Surgery, radiofrequency ablation, somatostatin
analogues
Age >60 years
15 M 58 Small intestine Surgery, transarterial chemoembolization,
somatostatin analogues
Transarterial chemoembolization
16 F 79 Small intestine Somatostatin analogues Age >60 years, hypertension, nephrectomy (left)
17 M 71 Pancreas Somatostatin analogues Age >60 years
18 F 43 Lung Surgery, somatostatin analogues –
19 F 65 Small intestine Chemotherapy, somatostatin analogues Age >60 years, hypertension
20 M 56 Small intestine Surgery, somatostatin analogues –
21 F 59 Small intestine Surgery, chemotherapy, interferon, somatostatin
analogues
–
22 F 42 Small intestine Surgery, somatostatin analogues –
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including the whole kidney parenchyma. All kidney
delineations were performed by the same observer. The
kidney mass of the phantom model in OLINDA/EXM
was adjusted using the kidney volume derived from CT
or MRI data.
90Y-Bremsstrahlung SPECT images were obtained at one
time-point after PRRT (18 h) on a single SPECT camera, as
a SPECT/CT camera had not been installed in our department
at the start of study. These images were only used as a
qualitative assessment; absolute quantification based on 90Y-
bremsstrahlung was beyond the scope of this study.
Pretherapeutic kidney dose estimation
Kidney dosimetry was assessed using the Medical Internal Ra-
diation Dose (MIRD) methodology, which assumes a uniform
activity distribution within the kidneys [26]. Since peptides are
mainly deposited in the proximal tubules in the renal cortex
which is associated with a greater radiobiological sensitivity,
the localization of the absorbed dose may increase the risk of
renal toxicity. In MIRD pamphlet no. 19, the kidney is further
divided into the cortex, medulla and renal pelvis compartments
which allows calculation of the average dose to the cortex [27].
Table 2 Treatment characteristics
Patient Body surface
area (m2)
Administered activities (MBq) Total
administered
activity (MBq)
Total
administered
activity (% BED)
Follow-up
(months)
Cycle 1 Cycle 2 Cycle 3 Cycle 4
1 1.72 2,949 3,004 3,041 3,090 12,081 400 41
2 1.82 3,482 3,541 3,304 3,574 13,901 400 18a
3 2.04 3,689 3,770 3,715 – 11,174c 300 22a
4 1.50 2,720 2,516 2,849 2,638 10,723 400 24a
5 2.25 4,096 3,837 4,166 4,148 16,247 400 27a
6 1.95 3,685 3,719 3,645 3,604 14,652 400 39
7 1.57 2,875 2,945 3,001 2,912 11,733 400 38
8 1.79 3,157 3,108 3,341 6,064 15,799 400 31
9 1.51 2,812 2,875 2,727 – 8,414b 300 34
10 1.82 3,482 3,263 3,441 – 10,186b 300 32
11 1.90 3,478 3,500 3,611 3,422 14,012 400 32
12 1.87 2,686 3,448 3,419 3,519 13,072 400 30
13 2.10 3,844 3,704 3,929 3,855 15,333 400 29
14 1.62 3,049 2,993 2,965 – 8,998b 300 28
15 2.08 3,848 3,578 3,867 3,904 15,196 400 27
16 1.53 2,612 2,842 2,979 – 8,432c 300 26
17 1.93 2,842 3,737 3,693 2,953 13,224b 380 24
18 1.76 3,252 3,282 3,138 3,067 12,739 400 22
19 1.58 2,882 2,505 2,975 – 8,362b 300 19a
20 1.79 3,279 3,282 3,286 3,289 13,135 400 21
21 1.71 3,167 3,186 3,234 3,149 12,735 400 20
22 1.84 3,434 3,271 3,400 3,415 13,520 400 18
Mean 1.80 3,157 3,268 3,351 3,538 12,280
Median 1.81 3,266 3,277 3,323 3,419 12,739 27
Minimum 1.50 2,612 2,505 2,727 2,638 8,362
Maximum 2.25 4,096 3,837 4,166 6,064 16,247
Standard
deviation
0.20 424 391 380 783 2,274
Interquartile
range
(Q1 – Q3)
1.64 – 1.92 2,877 – 3,482 2,996 – 3,569 3,011 – 3,637 3,084 – 3,667 10,836 – 13,806
Numbers that do not add up are due to rounding effects
a Patient died from tumour progression at that time during follow-up
b Reduced treatment activity because BED400% >37 Gy (dosimetry analysis)
c Reduced treatment activity because of only one functioning kidney
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The absorbed dose to the kidney was prospectively esti-
mated using the projected total administrated activity
(= projected absorbed dose at 400 % of one cycle), and retro-
spectively calculated, using the total administrated activity
(= absorbed dose for administered activity; Table 3) and the
results of OLINDA using the patients' kidney volume de-
rived from CTor MRI data. Barone et al. used the MIRD 19
models to demonstrate that the BED is a more appropriate
quantity than absorbed dose to predict the dose–response
relationship for renal toxicity in PRRT [18]. The BED
relates absorbed dose and dose rate to radiosensitivity and
repair using the linear quadratic model. More precisely, the
BED gives the absorbed dose that should be delivered to a
tissue for a certain biological effect at an infinitesimally
small dose rate and is useful for comparing treatments with
different dose rates and fractionation schemes. The use of
the BED concept for renal dosimetry was expanded upon in
MIRD pamphlet no. 20 [28]. The time of appearance and
dose-dependence of radiation damage in normal tissue de-
pend on its proliferative behaviour. For the kidney, the same
α/β ratio (2.6 Gy) and the same half-time of DNA repair
(2.8 h), as in the study Barone et al., were used and these
values are generally accepted in the literature. These fixed
numbers originate from data in a mouse model, although
analyses of data from human tissues on DNA repair kinetics
are in fact limited. However, the agreement between human
and animal data is generally considered acceptable [29].
The BED400% was defined as the cumulative projected
BED that a patient’s kidneys would receive if the patient
received the total activity scheduled in the study (i.e. BED
with four cycles at 100 % of one cycle, i.e. 400 % of one
cycle) and the BEDactual (i.e. cumulative BED for the total
actual administered activity) to the kidneys for every patient
was estimated with an extension of the BED using
biexponential clearance of the source organ based on the
method of Baechler et al. [26], in which the extended BED
relates the absorbed dose and time-dependent dose-rate with
radiosensitivity and repair of radiation damage using the stan-
dard linear quadratic (LQ) model. The following equation was
applied:
BED ¼ Di  1þ G Dið Þ
.
α=βð Þ
 
where Di is the kidney dose delivered per cycle i, α/β is the
quotient of the intrinsic radiosensitivity (α) and the potential
sparing (β) capacity of the kidney tissue which was set as α/
β=2.6 Gy [30], G is the Lea-Catcheside factor for a
biexponentially decaying source (see Eq. 14 in Baechler
et al. [26]) which is calculated using the effective clearance
rate constants λ1 and λ2, the dose-rate fraction coefficients of
the biexponential model and the exponential repair rate con-
stant μ (which quantifies the rate of sublethal damage repair
with μ=2.8 h) [26, 30].
To allow comparison with previously published BED re-
sults by Barone et al. [18], we recalculated our BED400% and
our BEDactual with the same equation as in that publication:
BED ¼
X
i
Di þ β=α T1=2 rep
.
T1=2 rep þ T1=2 eff
 
X
i
D2i
Where Di is the dose delivered for cycle i, T1/2 eff is the
effective half-life of 90Y-DOTATOC based on 111In-octreotide
renal clearance, T1/2 rep is the repair half-time of sublethal
damage with T1/2 rep=2.8 h and α/β=2.6 Gy as mentioned
above [10, 18, 21]. All BED results are presented in Table 4.
Table 3 Kidney parameters
Parameter Value
Kidney mass (g)
In 11 women (21 kidneysa)
Interquartile range (Q1 – Q3) 214 – 475
Mean 302
In 11 men (21 kidneysa)
Interquartile range (Q1 – Q3) 307 – 617
Mean 403
Treatment activity given (% of full dose) 400 % (in 15 patients)
300 % (in 6 patients)
380 % (in 1 patient)
Cumulative absorbed Dgiven activity to the kidneys (Gy)
Range 16 – 43
Mean 23
SD 6
Median 21
Interquartile range (Q1 – Q3) 20 – 25
Cumulative BEDgiven activity to the kidneys (Gy), biexponential fit
Range 18 – 31
Mean 27
SD 7
Median 24
Interquartile range (Q1 – Q3) 23 – 31
Cumulative BEDgiven activity to the kidneys (Gy), monoexponential fit
Range 19 – 55
Mean 29
SD 9
Median 27
Interquartile range (Q1 – Q3) 24 – 32
Dgiven activity Cumulative absorbed dose to the kidneys from the activity
which was given to the patient, BEDgiven activity cumulative biological
effective dose to the kidneys from the activity which was given to the
patient
a One patient with one functioning kidney
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Assessment of renal function
Renal function was evaluated using the series of tests shown
in Table 5.
Estimated glomerular filtration rate
Kidney function was assessed at baseline, and at 6, 12 and
18 months after PRRT. The serum creatinine concentration
was determined using the Jaffé method until October 2012 (in
20 patients) and an enzymatic method from November 2012
to the present (2 patients). However, both methods are trace-
able by isotope dilution mass spectrometry and differences
were proven to be negligible.
The eGFR was calculated using the MDRD (modification
of diet in renal disease) formula (supplementary data 2) [31].
The difference between serum creatinine and eGFR at
18 months and baseline (ΔS-creat and ΔeGFR) was
calculated.
Measured glomerular filtration rate
The measured GFR (mGFR) was determined by measuring
the clearance of the radiotracer 51Cr-EDTA. An activity of
3.7 MBq 51Cr-EDTA was injected intravenously and blood
samples were taken at 1, 2, 3 and 4 h after injection and the
51Cr-EDTA blood concentrations measured. mGFR was fur-
ther calculated by applying an appropriate mathematical
Table 4 Kidney doses
a See Baechler et al. [26]
b Probable overestimation of kid-
ney doses due to planar dosimetry
effects (superimposition of bowel/
liver metastasis on kidneys)
Patient BED400% (Gy) BEDactual (Gy)
Using linear
quadratic model with
monoexponential fit
Using extended
BED formulaa with
biexponential fit
Using linear
quadratic model with
monoexponential fit
Using extended
BED formulaa with
biexponential fit
1 29 27 27 25
2 26 24 26 25
3 36 34 27 25
4 26 24 25 23
5 26 24 25 23
6 21 20 21 21
7 24 22 24 22
8 29 28 28 27
9 73 52 55 39b
10 67 64 51 48b
11 19 18 19 18
12 32 30 30 28
13 25 24 25 23
14 44 45 33 34
15 24 23 24 23
16 26 25 19 18
17 43 40 40 37
18 24 23 24 22
19 52 48 37 34
20 22 21 22 21
21 36 34 36 34
22 28 26 27 26
Mean 33 31 29 27
Median 27 25 27 24
Minimum 19 18 19 18
Maximum 73 64 55 48
STDEV 15 12 9 7
Interquartile
range
(Q1 – Q3)
25 – 36 24 – 34 24 – 32 23 – 31
Eur J Nucl Med Mol Imaging
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model. The clearance of 51Cr-EDTA was calculated in all
patients at baseline and in 15 patients at 18 months after the
first treatment with 90Y-DOTATOC. The difference between
the mGFR at 18 months and the mGFR at baseline was
calculated (ΔmGFR). In the other seven patients, kidney
function was not assessed by 51Cr-EDTA clearance because
of declining health (four patients) and incomplete follow-up
(three patients), but the eGFR based on the MDRD formula
was used. The difference between eGFR at 18 months and at
baseline was also calculated (ΔeGFR).
It must be highlighted that aGFRL was never calculated
using different methods at baseline and target, so in these
seven patients the eGFR was used and in 15 patients the
mGFR was used at baseline and 18 months after the first cycle
of PRRT.
Annual glomerular filtration rate loss
The rate of renal function decline per year was expressed as
aGFRL (based on mGFR in 15 patients and on eGFR in 7
patients in whom mGFR was not available), and was calcu-
lated using both exponential and linear regression. The corre-
lations between aGFRL and relevant clinical parameters (kid-
ney size, BED, risk factors for renal function loss, kidney
volume and baseline GFR) were determined.
Kidney toxicity grade
The grade of kidney toxicity was assessed on the basis of GFR
at baseline and at 18 months using the Common Terminology
Criteria for Adverse Events (CTCAE) version 4.0 (see Sup-
plementary data 3). The correlations between kidney toxicity
grade and BED and renal function risk factors were deter-
mined. The hypothetical time for kidney function to reach
grade 4 toxicity was also calculated assuming that the rate of
kidney function loss (aGFRL) would remain constant by both
linear and exponential extrapolation.
Patients without renal function assessment at 18 months
In the 28 of 50 treated patients without renal function assess-
ment at 18 months the evolution of eGFR (from the MDRD
formula) and kidney toxicity until the last month before the
patient’s death were evaluated. aGFRL was also calculated in
patients surviving at least 9 months after PRRT (13 of 28,
46 %).
Statistical analysis
See Supplementary data 4.
Results
Clinical and treatment characteristics are presented in Tables 1
and 2, respectively, and kidney parameters in Table 3.
Renal function, kidney toxicity and risk factors
In all 50 patients, renal function was normal before treatment
with mGFR ranging from 50 to 128 ml/min/1.73 m2 (mean
79±19 ml/min/1.73 m2). Of the 50 treated patients, 22 were
available for kidney function assessment at 18 months
(Table 4; for the other patients, see section Patients without
renal function assessment at 18 months). The evolution of
their GFR over 18 months is shown in Fig. 1. No rapid
deterioration of kidney function (no creatinine increase of
>50 %) was observed during the 18-month follow-up. The
GFR, using mGFR in 15 patients and eGFR in 7 patients,
ranged from 35 to 116 ml/min/1.73 m2 (mean 72±19 ml/min/
1.73 m2, with a mean loss of 9.5±20.3 % and a maximal loss
of 36 % at 18 months. The mean difference between baseline
GFR and GFR at 18 months was 11±14 % (range −20 % to
33 %).
In all 22 patients with kidney follow-up at 18 months, the
mean exponential aGFRL after 90Y-DOTATOCPRRTwas 7±
9 % (range 0 to 23 %; Table 5). aGFRL was less than 10 % in
12 patients, less than 20% in 9 patients and more than 20% in
1 patient (patient 12). This patient had preexisting risk factors
for renal function loss (age >60 years and hypertension;
Table 1). In the total group of patients, there was no significant
difference in exponential aGFRL between patients with and
without risk factors (Fig. 2a; p=0.92; Wilcoxon rank-sum
test). In contrast to Imhof et al. [3], we found no significant
correlation between baseline GFR and aGFR loss (r = 0.29,
p = 0.18, Spearman correlation; Fig. 2b).
At 18 months, grade 1 nephrotoxicity was observed in two
patients and grade 2 nephrotoxicity in four patients; no rela-
tionship was found between the presence of preexisting risk
Fig. 1 Evolution of mean GFR over 18 months (absolute values) after
the first 90Y-DOTATOC PRRT cycle. No rapid deterioration in kidney
function is apparent (error bars SD)
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factors for renal function loss and kidney toxicity at 18months
(p>0.99, Fisher’s exact test; Fig. 3a). In the patient with
aGFRL >20 %, the kidney toxicity score remained 0. We also
examined the changes in kidney toxicity score between base-
line and 18 months: in 17 patients (77 %) the toxicity grade
was unchanged, in 3 patients (14 %) toxicity increased by one
grade, in 1 patient (4.5%) toxicity improved by one grade, and
in 1 patient (4.5 %) toxicity increased from grade 0 to grade 2
(Fig. 3b). In this last patient, however, right-sided
ureterolithiasis was discovered on a follow-up CT scan
12 months after PRRT that led to progressive hydronephrosis
and loss of kidney parenchyma, together with an increase in
creatinine clearance loss. Shock wave lithotripsy (SWL) was
performed at 25 months after PRRT that was followed by
stabilization, but without recovery of creatinine clearance.
Dimercaptosuccinic acid scintigraphy was also performed
after lithotripsy and showed diminished right kidney uptake
with absence of uptake in the upper pole. The contribution of
the right kidney to the total renal function was only 20 %. As
the mGFR at 18months was 54 ml/min/1.73m2, the extra loss
in GFR due to ureterolithiasis can be estimated at 38 ml/min/
1.73 m2 and the toxicity grade without would be 0.
The times to grade 4 toxicity estimated by linear extrapo-
lation (which yields less optimistic results than exponential
extrapolation) were ≥25 years in six patients (27%), ≥10 years
in four patients (18 %), ≥5 years in nine patients (41 %) and
<5 years in three patients (14 %; Table 5).
Kidney volume
The mean kidney volume was 302±70 ml in women and 403
±94 ml in men with wide ranges (214 – 475 ml in women and
307 – 617ml in men). In all the men and in 6 of the 11 women,
the kidney volumewas larger than the that of the standard Oak
Ridge National Library (ORNL) phantom [24]. No correlation
was found between kidney volume and renal function loss,
and in particular the presence of smaller kidneys was not
associated with a greater risk of renal function loss (Fig. 4a;
r=0.15, p=0.48, Spearman correlation). There was also no
significant correlation between kidney volume and BED
(Fig. 4b; r=−0.14, p=0.54, Spearman correlation).
Kidney BED assessment
Cumulative absorbed doses based on the actual total activity
that each patient received during PRRT ranged between 16
and 43 Gy (mean 23 Gy, median 21 Gy, interquartile range,
IQR, 20 – 25 Gy). The BED400% using the LQ model with
monoexponential fitting ranged between 19 and 73 Gy (mean
33±15 Gy, median 27 Gy, IQR 25 – 36 Gy) and between 18
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Fig. 2 aRelationship between
the presence of risk factors and
exponential aGFRL (p=0.92,
Wilcoxon rank-sum test). b
Relationship between baseline
GFR and aGFRL (r=0.29, p=
0.18, Spearman correlation)
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and 64 Gy (mean 31±12 Gy, median 25 Gy, IQR 24 – 34 Gy)
using the extended formula with biexponential fitting (Table 3).
The BEDactual calculated with the LQ model and
monoexponential fitting ranged between 19 and 55 Gy (mean
29±9 Gy, median 27 Gy, IQR 24 – 32 Gy). The BEDactual
calculated using the extended formula with biexponential fitting
ranged between 18 and 48 Gy (mean 27±7 Gy, median 24 Gy,
IQR 23 – 31 Gy; Tables 3 and 4). Overall, the BED400% and the
BEDactual values were slightly lower when the extended BED
formula was used, with a mean difference in BED400% of 6.5 %
(95% CI 4.2 – 8.8; p=0.01, paired t test) and in BEDactual of
6.4 % (95% CI 4.1 – 8.8; p=0.005, paired t test) with the
difference in BED400% ranging from −2.5 % to 29.1 % and
the difference in BEDactual from −2.7 % to 29.0 %.
Correlation between kidney BED and renal function loss
The calculated BED400% was below 37 Gy except in 5 of the 22
patients. Therefore, in these 5 patients, the total administered
activity was reduced to 300 % of one cycle in four patients and
380% in one patient, resulting in a BEDactual of <37 Gywith the
exception of patient 9 (BED400% 52 Gy, BEDactual 39 Gy) and
patient 10 (BED400% 64 Gy, BEDactual 48 Gy). In these patients
the results of dosimetry were not accurate because of superim-
position of bowel and liver metastasis over the kidney ROI
on the planar WB images and consequently a BEDactual higher
than 37 Gy (39 Gy and 48 Gy, respectively) was accepted
(Supplementary Fig. 3). This value has to be interpreted as an
upper boundary of BED, not as an accurate computation. Only
300 % of the activity of one cycle was also administered in the
two patients with only one functioning kidney (patients 3 and
16, BED400% 34 Gy and 25 Gy, respectively).
There was no significant correlation between kidney
BEDactual calculated with the extended BED formula and loss
in kidney function expressed as aGFRL (Fig. 5; r=0.07, p=
0.76, Spearman correlation). In patients 9 and 10 in whom
BEDactual exceeded 37 Gy aGFRL was 2 % and 20 %, respec-
tively, which is within the range observed in the other patients,
confirming the hypothesis that these BEDactual values are
overestimated. In the two patients with dose reduction due to
only one functioning kidney, the aGFRL was 6 % in patient 3
and no aGFRL was observed in patient 16.
We also compared the observed aGFRL in all 22 patients
with the data from the 18 patients investigated by Barone et al.
[18]. We used BEDactual calculated with the LQ model with
monoexponential fitting (the same method as used by Barone
Fig. 3 aRelationship between
BEDactual and kidney toxicity in
22 patients. The filled circles
represent patients with risk factors
for renal function loss (15
patients), and the open circles
patients without risk factors (7
patients). The red circles represent
the two patients with >37 Gy
kidney BEDactual with
overestimation of the dosimetric
result; both also had risk factors
(three points are slightly
misplaced to avoid overlap). b, c
Evolution of kidney toxicity
grade in relation to baseline (b) at
18 months in 22 patients with
intense assessment of renal
function evolution, and (c) at the
time of the last follow-up in 28
patients who did not survive until
the 18-month time-point
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et al.) and the corresponding observed aGFRL in our patients
and added these data to the published graph of Barone et al.
(Fig. 6). None of the patients in our series showed an increase
in aGFRL of >33 %, not even the two treated patients with a
BEDactual >37 Gy. Furthermore, most of our data points were
located to the left of the fit. In the BEDactual range between 20
and 30 Gy, the dose–effect curve of Barone et al. underesti-
mates the aGFRL by an average of 8.8 % (95% CI 5.0 – 12.7,
p=0.002, paired t test).
Finally, we examined the benefit of activity reduction in the
five patients with BED400% >37 Gy and the two patients with
only one functioning kidney. We calculated the aGFRL, in
terms of full treatment activity (400 %) and using the fit of the
BED–aGFRL graph of Barone et al. [18], and compared it to
the observed aGFRL (Table 6). There was a benefit in four out
of the seven patients (mean 9.4 ± 17.3 %, range
−10.5 – 39.9 %). The best results were obtained in patients 9
and 10 in whom the BED was overestimated due to
superimposition.
Patients without renal function assessment at 18 months
In these 28 out of the 50 treated patients, the mean kidney
follow-up time assessing eGFR was 7 months (range 0.5 –
18 months). Based on their BED result, the treatment activity
was reduced in 16 of these 28 patients, and in two patients
PRRT was ended after one cycle because of aberrant
biodistribution of 68Ga-DOTATOC imaging at week 7
(BEDactual 3.3 Gy and 8.4 Gy) [19]. Only 15 of the 28 patients
received the prescribed activity; the other 13 died during
PRRT because of disease progression. There was no marked
decrease in eGFR observed in 27 out of those 28 patients. In
the 13 patients who reached the 9-month time-point after the
first PRRT, aGFRL ranged from 0 % to 32 %, except in one
patient with aGFRL of 66 %. The toxicity grade stayed the
same in 19 patients or decreased one or two grades in 3
patients during PRRT. The toxicity grade increased in four
patients, by one grade in two and by two grades in two, during
therapy (Fig. 3c). The patient with aGFRL of 66 % developed
renal failure and grade 4 nephrotoxicity (starting with grade 0
toxicity at baseline) at 15 months with serum creatinine
8.4 mg/dl and eGFR <15 ml/min/1.73 m2 (Supplementary
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Fig. 4 Relationships between kidney size and (a) aGFRL (r=0.15, p=
0.48, Spearman correlation), and (b) BEDactual (r=−0.14, p=0.54, Spear-
man correlation) in 22 patients. The red diamonds represent the two
patients with kidney BEDactual >37 Gy with overestimation of the dosi-
metric result. Correlations were not significant
Fig. 5 Relationship between
BEDactual and aGFRL in 22
patients. The filled circles
represent patients with risk
factors. The correlation between
BEDactual and aGFRL was not
significant (p=0.76, r=0.07,
Spearman correlation)
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data 5). A kidney biopsy showed moderate acute tubule
necrosis; there were no positive arguments for thrombotic
microangiopathy.
Two patients were excluded from the study because the
calculated kidney BED was so high that even a minimum of
three cycles at 100 % activity exceeded 37 Gy (BED400%
57 Gy and 64 Gy).
Discussion
The kidney is the major critical organ during PRRT. After
filtration by the glomeruli, radiolabelled peptides are
reabsorbed and retained in the proximal tubular cells [32].
Due to the activity present in the (relatively radioresistant)
tubular cells, renal toxicity arises through irradiation of the
radiosensitive glomeruli and medulla [12, 14, 33]. With ex-
ternal beam radiotherapy (EBRT), the critical dose to the
kidney is 23 Gy. At this dose, a 5 % probability of attaining
radiation nephropathy within 5 years has been reported [10,
18, 30, 34]. The LQ model can be used to convert the EBRT
dose limit to a corresponding limit in radionuclide therapy
[30]. Barone et al. [18] have calculated the tissue complication
probability curve for 90Y-DOTATOC-PRRT, relating the kid-
ney BED to aGFRL. They showed that the probability in-
creases at 37 Gy BED.
The objective of this study was to use prospective individ-
ualized dosimetry data to administer 90Y-DOTATOC up to a
maximum kidney BED threshold of 37 Gy. There are some
differences between our study and that of Barone et al.: (1)
different patient population, (2) different dosimetry tracer
(111In-octreotide versus 86Y-DOTATOC); (3) different dosim-
etry methodology (planar vs. tomographic). In the BEDactual
range between 20 and 30 Gy, the Normal Tissue Complication
Probability (NTCP) curve of Barone et al. underestimates the
aGFRL by an average of 6.7 % which can be explained by the
different dosimetry protocols used. Nevertheless, none of our
patients showed pronounced and rapid kidney function dete-
rioration, and the aGFR loss was acceptable in every patient.
This observation prospectively validates the use of the 37 Gy
BED as a critical dose threshold predicting rapid kidney
deterioration.
From among the 50 patients included in the study, we
thoroughly studied the 22 who survived until the 18-month
follow-up time-point, but we also looked at the data from the
28 other patients who died or were lost to follow-up before
18 months after PRRT. Two of those 22 patients received a
total administered activity that resulted in a calculated
BEDactual of >37 Gy (patients 9 and 10). This value is an
upper limit and not an accurate estimate because of superim-
position effects during planar dosimetry.
We found no correlation between kidney size and aGFRL.
This was expected because the individual kidney volumes
were already taken into consideration during dosimetry by
delineating the kidneys on CT or MRI images and replacing
the phantom kidney values in OLINDA by the individual
volumes in every patient. When calculating the BED to the
kidneys using fixed administered activity protocols and using
standard kidney volumes instead of individual kidney size, the
renal dose would be underestimated if the kidneys are smaller
than those of the standard model. This is explained by the
concentration of the same activity in a smaller volume, which
increases the radiation dose to the kidneys. Pauwels et al. [7]
prospectively calculated the absorbed doses to the kidneys
using standard ORNL volumes, and found that smaller kid-
neys have a greater risk of function loss. If the kidney size is
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Fig. 6 Relationship between
BEDactual (using the LQ model
withmonoexponential fitting) and
aGFRL. The red crosses are the
data of Barone et al. [18], the
green triangles are our data from
22 patients. None of our patients
showed an increase in aGFRL of
>33 %, not even the two treated
patients with a BEDactual >37 Gy
(red triangles). This prospectively
validates the use of the 37 Gy
BED threshold proposed by
Barone et al. [18]. Furthermore,
most of our data points are located
to the left of the fit
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known, the decision whether or not to perform PRRT should
be taken after dosimetry based on the actual kidney size.
Taking the risk factors for kidney function loss described
by Bodei et al. [10] and Imhof et al. [3] into account, no
significant difference in aGFRL was found between patients
with and without risk factors. It needs to be emphasized that
no dosimetry was performed in the patients from the series of
Imhof et al. This supports the hypothesis that it is not the
presence of risk factors, but the actual dose delivered to the
kidneys that is more important for predicting kidney toxicity.
Patients with risk factors should not be treated differently
based only on the presence of these risk factors, but should
be treated according to their individual kidney BED.
Valkema et al. found a median decline in creatinine clear-
ance of 7.3 % per year in patients treated with 90Y-DOTATOC
and 3.8 % per year in patients treated with 177Lu-DOTATATE
[12]. This difference was explained by the type of β-particle,
and more specifically the range of the β-particle, used for
therapy. The range of β-particles from 90Y is maximally
12 mm, and the range of the 177Lu electrons is maximally
2.1 mm. As the average distance from the tubular uptake and
the glomerulus is important for the estimation of the radiation
damage after PRRT, the sensitive glomeruli may be partially
spared using 177Lu, the range of 90Yon the other hand is long
enough to reach the glomeruli. This means that 1 Gy from
177Lu may lead to a lower average glomerular dose than 1 Gy
from 90Y, and this may be an additional explanation for the
much lower average decline in creatinine clearance in the
patients treated with 177Lu-DOTATATE than in those treated
with 90Y-DOTATOC. In a very recent study, Romer et al. [35]
found that the rate of severe permanent renal toxicities was
similar for 90Y-DOTATOC and 177Lu-DOTATOC (9.2 % and
7.8 % respectively; p=0.32). According to this study, 177Lu-
labelled peptides could cause just as much renal toxicity as
90Y-labelled peptides. However, a possible bias in this study
cannot be excluded as the study was not randomized. Ideally, a
randomized controlled clinical trial should be performed.
Among the 1,109 patients treated with 90Y-DOTATOC by
Imhof et al. [3], 9 % developed severe permanent renal toxic-
ity after PRRT and in an earlier study by Bodei et al. [10],
WHO grade 1 – 3 creatinine toxicity was seen in 9 of 23
patients selected for dosimetric studies from a group of 211
patients. In the study by Imhof et al. it is not clear if all patients
received the same amino acid combination. and in the study
by Bodei et al. four of the nine patients with renal function
impairment did not receive any amino acids. In a multicentre
trial [4], transient grade 3 or 4 renal toxicity was seen in 3 of
90 patients (3 %). In studies by Kwekkeboom et al. [36, 37],
no renal toxicity was seen after treatment with 177Lu-
octreotate, but the follow-up period was no longer than
Table 6 aGRFL based on the LQ
model (similar to the calculations
of Barone et al. [18])
aGFRL annual rate of GFR loss
determined using exponential
fitting of GFR values calculated
using 51 Cr-EDTA except in pa-
tients 2, 3. 4, 15, 16, 18 and 19 in
whom it was estimated using se-
rum creatinine at 12 months or at
18 months, both using theMDRD
formula
a Projected aGFRL at 400% treat-
ment activity
b aGFRL calculated for given
activity
c Observed aGFRL
d Patients in whom the dose was
reduced because of a projected
BED of >37 Gy or because of
only one functioning kidney
e Beneficial effect of dose reduc-
tion on aGFRL
Patient BED400%
(Gy)
aGFRL400%
(%)a
BEDactual
(Gy)
aGFRLactual
(Gy)b
aGFRLobserved
(%)c
ΔaGFRL
(actual – observed)
1 29 0.6 27 0.3 2.0 −1.7
2 26 0.1 26 0.2 11.2 −11.1
3d 36 4.4 27 0.2 5.4 −5.2
4 26 0.2 25 0.1 11.3 −11.2
5 26 0.1 25 0.1 15.3 −15.2
6 21 0.0 21 0.0 15.3 −15.2
7 24 0.0 24 0.1 11.7 −11.6
8 29 0.7 28 0.4 8.2 −7.7
9d 73 77.0 55 41.9 2.0 39.9
10d 67 67.8 51 31.9 19.7 12.2
11 19 0.0 19 0.0 −7.2 7.2
12 32 1.5 30 0.8 23.4 −22.6
13 25 0.1 25 0.1 −3.3 3.4
14d 44 16.4 33 2.2 3.4 −1.2
15 24 0.1 24 0.0 10.4 −10.4
16d 26 0.2 19 0.0 −9.4 9.4
17d 43 14.1 40 8.6 −12.9 21.5
18 24 0.1 24 0.0 2.1 −2.0
19d 52 35.0 37 5.1 15.6 −10.5
20 22 0.0 22 0.0 7.5 −7.5
21 36 4.2 36 4.3 16.0 −11.6
22 28 0.3 27 0.3 6.1 −5.8
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6 months which is insufficient to predict long-term renal
toxicity after treatment with 177Lu-DOTATATE.
There were a number of limitations to this study. Our
study population was small (22 of 50 treated patients, as
only 22 patients survived until the 18-month time-point),
but this is in line with other dosimetry studies that also
looked at patient populations of similar size (e.g. 28 pa-
tients [10], 18 patients [18]). Our study population com-
prised all successive patients eligible for treatment within
the study. We had insufficient follow-up to assess long-term
kidney function outcome.
We used a dosimetry protocol with sequential 111In-
pentetreotide WB scans for calculation of quantitative dosim-
etry. SPECTacquisitions were only used for visual assessment
in the event of superimposition, not for quantitative assess-
ment. However, multiple WB scans can offer sufficient infor-
mation on biodistribution and its variation over time [21]. The
introduction of SPECT/CTwould allow refinement of dosim-
etry procedures and multiple SPECT/CT acquisitions of, for
example, the critical organs and/or principal tumour burden
are advocated. This study was initiated before the installation
of a SPECT/CT system in our department, so its use was not
an option. We observed some patients in whom pure planar
dosimetry resulted in overestimation of organ doses due to
superimposition of metastasis or bowel activity over kidney
tissue; a SPECT(/CT)-based dosimetry approach would have
overcome this limitation. Nevertheless, rapid deterioration in
kidney function was observed in only one patient. Although
the pathology report did not show the hallmarks of nephro-
toxicity after PRRT, a possible influence of PRRT has to be
assumed. The subsequent aGFR loss was acceptable in every
patient up to 18 months, with exception of the aforementioned
patient (1 of 50, 2 %).
Dosimetry with 86Y-DOTATOC seems theoretically
more suitable as 86Y is the almost perfect chemical surro-
gate for 90Y and makes high-resolution PET possible, but
86Y-DOTATOC has a short half-life (14.7 h), has low
availability and interferes with high-energy gamma rays,
which reduce the feasibility and accuracy of the data
collection for dosimetry. 111111In-Octreotide on the other
hand is approved by EMA, is reimbursed and commer-
cially available. 86Y-DOTATOC was not available in our
country for legal and logistic reasons. Helisch et al. [23]
and Förster et al. [22] compared the biodistribution of
86Y-DOTATOC with that of 111In-pentetreotide and con-
cluded that adequate dosimetry prior to 90Y-DOTATOC ther-
apy is mandatory and that kidney dosimetry with both com-
pounds is possible and similar. 111In-Pentetreotide also has a
very important advantage for dosimetry compared to 86Y-
DOTATOC, as the physical half-life of 111In is 67.3 h,
and is thus comparable with that of 90Y (64 h) and with
the biological half-life of peptides, which allows derivation
of time–activity curves.
Other radiotracers that can be used for dosimetry in 90Y-
DOTATOC PRRT are 111In-DOTATOC, 90Y-bremsstrahlung
planar images or SPECT and 90Y-PET images. Some authors
have suggested the use of 111In-DOTATOC because it mimics
the therapeutic agent better than 111In-DTPA-octreotide, and
this agent has been used in some clinical protocols for dosi-
metric purposes. Conventional bremsstrahlung imaging is
already widely used for assessing biodistribution after 90Y-
ibritumomab tiuxetan therapy, and after 90Y-SIR therapy. The
use of 90Y-bremsstrahlung images for dosimetry after 90Y-
DOTATOC PRRT is still under investigation. Fabbri et al.
have shown that 90Y-bremsstrahlung images acquired and
reconstructed by hybrid SPECT/CT systems using adequate
calibration factors can provide better information on distribu-
tion and biokinetics of 90Y-DOTATOC, and that patient-
specific dosimetry is feasible with acceptable accuracy fol-
lowing each therapy cycle [38]. 90Y-PET acquisition has been
shown to be feasible for dosimetry assessment after liver SIRT
in an anatomical phantom as well as in a patient [39, 40]. In a
phantom study, Walrand et al. found that 90Y-DOTATOC PET
can be used for kidney dosimetry, but this is currently not
being done on patient data [41]. This has to be further
explored.
Finally, to allow comparison with previously published
BED results [18], we recalculated our BED400% and our
BEDactual using the same equation as used in the previous
study. However, in contrast to Barone et al., who used a linear
(4 – 24 h) and a monoexponential (24 – 48 h) fit, we used a
monoexponential fit to our four data points, assuming that this
did not lead to any relevant changes in outcome.
Despite the different chemical structures, the different ra-
dionuclides and peptides and the different dosimetry proto-
cols, the proposed approach has been shown to be sufficiently
reliable to correctly predict a high radiation burden to critical
organs. At the time of initiation of the study in 2008, planar
dosimetry was still standard and a SPECT/CT system was not
yet available in our department. Dosimetry refinement was not
the main objective of our study and we opted for a protocol
feasible in patients receiving antiemetogenic medication. We
used the dosimetry results as a tool to improve the safety of
PRRT administration. We opted for serial planar dosimetry
using a predefined threshold of 37 Gy BED from the model of
Barone et al. This objective was achieved, as rapid deteriora-
tion in kidney function and evolution to severe nephrotoxicity
was avoided in 98 % of the patients (49 of 50), which is a
result similar to or better than found in other 90Y-DOTATOC
PRRT studies with [7, 12] or without [3, 4] tomographic
dosimetry.
Over the last 5 years, much effort has been directed towards
improving the accuracy of image analysis and quantification
for dosimetry (e.g. 3-D quantitative SPECT imaging as de-
tailed in MIRD 23, individualized Monte Carlo simulations,
voxel-level analysis, correction methods for positron emitters
Eur J Nucl Med Mol Imaging
with coemission of high-energy photons). We therefore advo-
cate the use of quantitative SPECT/CT in future dosimetry
studies in accordance with MIRD 23, as it would allow
refinement of dosimetry compared to planar imaging based
dosimetry, especially when superimposition of tumour or
physiological activity over the kidney tissue is suspected.
Conclusion
Our observations confirm that a prospective dosimetry proto-
col in which an amino-acid solution is simultaneously
coadministered and in which a BED of 37 Gy is used as a
threshold for kidney toxicity based on published data [18] is a
good guide for 90Y-DOTATOC PRRT. The use of this proto-
col avoided rapid deterioration in renal function and evolution
to severe nephrotoxicity in 98 % of patients (49 of 50).
Although this dosimetry protocol has its shortcomings, it is
feasible in nuclear medicine departments for those seeking to
become familiar with PRRT if basic equipment and trained
personnel are available. Moreover, this dosimetry protocol
results in an acceptable clinical outcome, especially in patients
with a high kidney BED.
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